Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, Daud A, Car - lino MS, McNeil CM, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol.